References Deanfield, John et al., Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial, The Lancet, Published on October 22, 2025, DOI: 10.1016/S0140-6736(25)01375-3 Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity (SELECT), ClinicalTrials.gov ID NCT03574597,
These hormones are rapidly inactivated by the enzyme DPP-4
Retrospective studies show modest weight loss, around 3% to 5% over 6 to 12 months, less than in the general population
BCAA+GLUTAMINE XPRESS provides these amino acids in exceptionally delicious flavours
Safety and tolerability of diazoxide in Japanese patients with hyperinsulinemic hypoglycemia